Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Radnor, Pennsylvania, has reported that its Board of Directors' Compensation Committee granted inducement awards to two new non-executive employees on February 9, 2026. These awards, totaling 33,504 stock options and 25,128 restricted stock units, are part of the company’s 2025 Employment Inducement Incentive Award Plan, created to attract and retain new talent in the competitive biopharmaceutical industry.

The stock options will vest over four years, beginning with 25% on the first anniversary of the award's vesting commencement date. An incremental 1/48th of the total shares will then vest monthly thereafter, contingent upon the employees’ continued service with the company. Similarly, the restricted stock units will also vest over four years, with 25% of shares vesting on each of the four anniversaries starting February 9, 2026.

These inducement awards were issued in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to provide equity compensation to new employees as an incentive to join the organization.

Mineralys Therapeutics specializes in developing targeted treatments for hypertension and associated comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA), primarily through its lead candidate, lorundrostat. This product is a proprietary, orally administered aldosterone synthase inhibitor aimed at addressing diseases linked to dysregulated aldosterone levels. The company was founded by Catalys Pacific and continues to make strides in the biopharmaceutical sector.

For further details about the company and its developments, visit their website at mineralystx.com and follow them on LinkedIn, Twitter, and Bluesky.

Mineralys Therapeutics (Nasdaq: MLYS), a clinical-stage biopharmaceutical firm focused on hypertension and related comorbidities, has granted inducement stock option and restricted stock unit awards to attract new talent under Nasdaq's Listing Rule 5635(c)(4). This strategic move signals Mineralys' commitment to building a robust team, which is essential for navigating the competitive landscape of biopharmaceutical development, particularly as it seeks to advance its lead product candidate, lorundrostat.

The awarded stock options covering 33,504 shares and restricted stock units for 25,128 shares will vest over four years, indicating a structured timeline aimed at aligning employee incentives with the company's long-term goals. By tying compensation to the stock's performance, Mineralys not only motivates these new hires but also strengthens their commitment to the company’s success in bringing innovative treatments to market.

From an investment perspective, the issuance of these inducement awards can be seen as a positive sign. It highlights the company's ambition to attract and retain high-caliber talent, which is crucial in the clinical development phase, especially given the complexities of bringing new therapies to market. Furthermore, the focus on conditions like CKD and OSA, which have substantial unmet medical needs, positions Mineralys well for potential future growth, assuming clinical success.

Investors should closely monitor Mineralys' progress on clinical trials and any forthcoming data releases related to lorundrostat’s efficacy and safety. The biopharmaceutical sector is highly sensitive to such developments, and positive results can lead to significant stock appreciation.

In conclusion, while the current granting of inducement awards signals enhanced employee engagement and alignment with corporate goals, prospective investors should remain informed about the company's clinical journey and overall market environment as they consider their positions in Mineralys Therapeutics.